Top in GI: Infliximab retreatment; short bowel syndrome guidance
Click Here to Manage Email Alerts
After 26 weeks of retreatment with infliximab, 35% of patients with Crohn’s disease achieved remission, according to recent data.
Researchers said there was no significant difference between rates of clinical remission in patients who previously discontinued infliximab due to loss of response vs. intolerance. It was the top story in gastroenterology last week.
Another top story covered the American Gastroenterological Association’s clinical practice recommendations for the management of short bowel syndrome.
Read these and more top stories in gastroenterology below:
Infliximab retreatment results in remission in 35% of patients with Crohn’s disease
After previously discontinuing infliximab, 35% of patients with Crohn’s disease achieved remission at 26 weeks with drug retreatment, according to a study published in The American Journal of Gastroenterology. Read more.
AGA offers 12 best practice recommendations for managing short bowel syndrome
The AGA has released a clinical practice update and expert review on the characterization and management of patients with short bowel syndrome, which recently was published in Clinical Gastroenterology and Hepatology. Read more.
Q&A: Updated ACG monograph provides guidance for GI care during pregnancy, postpartum
The ACG has published a supplement to The American Journal of Gastroenterology with updated recommendations for the management of gastrointestinal disorders in patients who are pregnant or in the postpartum period. Read more.
Obeticholic acid flops in phase 3 trial for compensated NASH-related cirrhosis
Obeticholic acid failed to demonstrate superiority to placebo for improving fibrosis in patients with compensated cirrhosis due to nonalcoholic steatohepatitis in a phase 3 trial, according to an Intercept Pharmaceuticals press release. Read more.
Obeticholic acid yields fewer deaths, liver transplants in primary biliary cholangitis Patients who received obeticholic acid for primary biliary cholangitis experienced greater transplant-free survival compared with external control patients, according to research published in Gastroenterology. Read more.